SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive: Next, we tried to explore the diagnostic impact of the SKP2 gene; the ROC analysis revealed that the best cut-off value for the SKP2 gene expression level that differentiated the CML patients from the healthy subjects (control group) was >1.08, yielding sensitivities of 86.0% and 82.0%, with an AUC of 0.958 (p < 0.001) (Figure 3), suggesting that SKP2 gene expression could be an additional diagnostic marker for CML.